Biolidics (SGX:8YY) EBIT : S$-3.08 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Biolidics EBIT?

Biolidics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was S$-0.41 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was S$-3.08 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biolidics's annualized ROC % for the quarter that ended in Sep. 2024 was -60.04%. Biolidics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -2,197.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biolidics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -8.89%.

Biolidics EBIT Historical Data

The historical data trend for Biolidics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolidics EBIT Chart

Biolidics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-4.80

-4.56

-5.83

-9.68

-2.38

Biolidics Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															-0.36	-1.36	-0.75	-0.56	-0.41

Competitive Comparison of Biolidics's EBIT

For the Diagnostics & Research subindustry, Biolidics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolidics's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biolidics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biolidics's EV-to-EBIT falls into.

Biolidics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-3.08 Mil.

Biolidics (SGX:8YY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biolidics's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-1.084 * ( 1 - 0% )	/	( (2.343	+	1.268)	/ 2 )
=	-1.084	/	1.8055
=	-60.04 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.545	-	0.472	-	( 0.15	-	max(0, 2.733	-	0.463	+	0.15	))
=	2.343

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.504	-	2.036	-	( 0.166	-	max(0, 3.236	-	0.436	+	0.166	))
=	1.268

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Biolidics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.648	/	( ( (0.082 + max(-1.416, 0))	+	(0.068 + max(-2.136, 0)) )	/	2 )
=	-1.648	/	( ( 0.082	+	0.068 )	/	2 )
=	-1.648	/	0.075
=	-2,197.33 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.008	+	0	+	0.235)	-	(0.472	+	0	+	1.187)
=	-1.416

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.001	+	0	+	0.219)	-	(2.036	+	0	+	0.32)
=	-2.136

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biolidics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-3.076	/	34.605
	=	-8.89 %

Biolidics EBIT Related Terms

Thank you for viewing the detailed overview of Biolidics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolidics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biolidics Ltd (SGX:8YY) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Howard Road, No. 11-09 Novelty BizCentre, Singapore, SGP, 369585

Website

https://www.biolidics.com

Biolidics Ltd is engaged in technology development, technology transfer, marketing, sale and distribution of biomedical technology, life, and medicine science-related products and services, and investment holding. The company's business segments are; Cancer, Infectious diseases, Laboratory services, and Corporate. The majority of the company's revenue is generated from the laboratory services segment which involves the business, operation, and provision of laboratory services to customers. Its operations are spread across Singapore, Japan, China, Europe, the United States, Hong Kong, the Philippines, Indonesia, and Others.

Biolidics Headlines

No Headlines